Haemophilia Forecast in 17 Major Markets 2017-2027 - Research and Markets

DUBLIN--()--The "Haemophilia Forecast in 17 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Haemophilia is a collective term describing rare, usually inherited genetic blood coagulation disorders that lead to abnormally long bleeding at the site of wound or injury and, in severe cases, spontaneous bleeding episodes without any apparent injury. The disorders are caused by absent or insufficient activity of blood coagulation factors.

This report covers the two main types of the disease, haemophilia A (factor VIII deficiency) and B (factor IX deficiency), both of which are X-linked recessive disorders that are much more common in males, as well as acquired haemophilia, a very rare autoimmune disorder caused by abnormal immune system autoreactivity, resulting in clotting factor deficiency (usually factor VIII) and signs and symptoms similar to those of HA/HB.

This report provides the current prevalent population for haemophilia across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Greece, Turkey, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, sub-populations with the covered types of haemophilia, as well as several of the main symptoms and co-morbidities of haemophilia and clinical features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for haemophilia include:

  • Development of inhibitors
  • Haemophilic arthropathy
  • Reduced bone density
  • Cirrhosis
  • Hepatocellular carcinoma

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid Conditions / Features Associated With the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Haemophilia

10. Features of Haemophilia Patients

11. Haemophilia a Patients

12. Haemophilia B Patients

13. Acquired Haemophilia Patients

14. Comorbid Conditions of Haemophilia Patients

15. Haemophilic Arthropathy

16. Other Comorbid Conditions

17. Abbreviations Used in the Report

18. Other Publications

19. Patient-Based Databases

20. Patient-Based Offering

21. Online Pricing Data & Platforms

22. References

23. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/bjv89f/haemophilia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematology